Effect of simvastatin on bone markers in osteopenic women: a placebo-controlled, dose-ranging trial
Completed
- Conditions
- OsteopeniaMusculoskeletal DiseasesBone density disorders
- Registration Number
- ISRCTN85429598
- Lead Sponsor
- George Washington University (USA)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Female
- Target Recruitment
- 24
Inclusion Criteria
1. Women with osteopenia
2. Not taking oestrogen
3. Selective oestrogen receptor modulators
4. Bisphosphonates
5. Calcitonin
6. 3-hydroxy-3-methylglutaryl coenzyme A (HMG-coA) reductase inhibitors
Exclusion Criteria
Not provided at time of registration
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ot provided at time of registration
- Secondary Outcome Measures
Name Time Method ot provided at time of registration
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does simvastatin use to affect bone markers in osteopenic women?
How does simvastatin compare to standard osteoporosis treatments in improving bone density?
Which biomarkers are associated with simvastatin's efficacy in osteopenia management?
What are the potential adverse events of simvastatin in bone density disorders and how are they managed?
Are there combination therapies involving simvastatin and other HMG-CoA reductase inhibitors for musculoskeletal diseases?